Neubin Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 12-01-2025
- Paid Up Capital ₹ 1.50 M
as on 12-01-2025
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.88 Cr
as on 12-01-2025
- Satisfied Charges ₹ 2.70 Cr
as on 12-01-2025
- Revenue %
(FY 2022)
- Profit -47.26%
(FY 2022)
- Ebitda -50.00%
(FY 2022)
- Net Worth -1.01%
(FY 2022)
- Total Assets 736.08%
(FY 2022)
About Neubin Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹2.88 Cr. The company has closed loans amounting to ₹2.70 Cr, as per Ministry of Corporate Affairs (MCA) records.
Uma Rani and Raghav Goel serve as directors at the Company.
- CIN/LLPIN
U24290UR2020PTC011353
- Company No.
011353
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Aug 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Haridwar, Uttarakhand, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Neubin Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Uma Rani  | Director | 19-Sep-2020 | Current |
| Raghav Goel | Director | 19-Sep-2020 | Current |
Financial Performance of Neubin Life Sciences.
Neubin Life Sciences Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 47.26% decrease in profit. The company's net worth dipped by a decrease of 1.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neubin Life Sciences?
In 2022, Neubin Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 14 Mar 2024 | ₹1.27 M | Open |
Hdfc Bank Limited Creation Date: 10 Jan 2024 | ₹2.75 Cr | Open |
Others Creation Date: 27 Jan 2022 | ₹2.70 Cr | Satisfied |
How Many Employees Work at Neubin Life Sciences?
Neubin Life Sciences has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neubin Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neubin Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
